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Abstract
Background
Health care associated urinary tract infections (HAUTI) is a common complicating factor
of urological practice. It is unclear what the appropriate empirical antibiotic choices are
and how infection control policies (ICP) influence this. The aim of this study is to use prob-
abilistic approaches towards the problem. That is to determine the chances of coverage
of empirical antibiotic choices in HAUTIs and their annual trends in Europe. In addition,
the impact of departmental self-reported compliance with catheter management and reg-
ulated usage of prophylactic antibiotics policies was tested. The estimated chances of
coverage of antibiotics and further probabilistic calculations are carried out using the
Global Prevalence of Infections in Urology (GPIU) annual surveillance study European
data.
Methods
GPIU is a multi-state annual prevalence study conducted in urology departments to
detect patients with HAUTIs, using the Center for Disease Control (CDC) definitions and
antimicrobial resistance (AMR). In this analysis; the European cohort from 2005 to 2015
was used. The estimated chance of coverage for each antibiotic choice in HAUTIs was
calculated using the Bayesian Weighted Incidence Syndromic Antibiogram (WISCA)
approach. Annual trend of the overall cohort and number of appropriate antibiotic choices
were estimated. Departments were compared according to their self-reported compliance
to ICPs to determine if there was an impact on chances of coverage and appropriate anti-
biotic choices.
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Results
We estimated that in most study years less than half of the single agent antibiotics and all
combination options were appropriate for empirical treatment of HAUTIs. Departments with
compliance to both ICPs were estimated to have 66%(2006) to 44% (2015) more antibiotic
choices compared to departments with complete lack of compliance to the ICPs. In our esti-
mates departments with adherence to a single policy was not superior to departments with
complete lack of adherence to ICPs.
Conclusions
Most single agent choices had limited coverage for HAUTIs and combination choices had
improved chance of coverage. Optimal antibiotic selection decision should be part of deci-
sion experiments and tested in local surveillance studies. Departments with self-reported
compliance to ICPs have more antibiotic choices and details of the compliance should be
evaluated in future studies. The analysis herein showed that over the 10-year course there
was no clear time trend in the chances of coverage of antibiotics (Bayesian WISCA) in Euro-
pean urology departments.
Introduction
Health care associated urinary tract infections (HAUTI) in urology are a complicating factor
of health care and their prevalence is estimated to be 7.7% [1]. Unfortunately, their prevention
by using prophylaxis and treatment with antibiotics is hindered by the high levels of antimi-
crobial resistance (AMR). Despite recommendations on prudent use of antibiotics, misuse of
antibiotics is an ongoing issue and escalates AMR in health care [2, 3]. Tackling AMR is of par-
amount importance to maintain availability of efficacious antibiotics. One of the recom-
mended strategies to tackle AMR is to conduct surveillance of AMR to help selection of
appropriate empirical antibiotic treatment and improve policy making [4].
Although, surveillance data is useful for clinical decision making (stewardship) and policy
development, has some limitations. The main one is derived from the conventional
approaches to synthesize AMR data, which focus on the pathogens and their susceptibility pro-
file for each antibiotic choice. Whereas, from a stewardship and clinical point of view for
selecting the appropriate empirical treatment the more relevant question is: “Which antibiotic
works best for the condition being treated?”. An alternative way to answer this question is
through a compound measure called weighted incidence syndromic combination antibio-
grams (WISCA) [5]. This is derived from surveillance data and calculated by obtaining the
cumulative sum of the relative incidence of each pathogen multiplied with the chances of sus-
ceptibility. The WISCA tool provides the expected coverage of a select antibiotic regimen in
terms of probabilities and allows direct comparison between different antibiotics on the same
scale.
While, WISCA can improve utility of AMR surveillance information it cannot adequately
handle information regarding rare pathogens and sequential surveillance data. Within a finite
sample obtained from surveillance, rare pathogens might not be present although the likeli-
hood of them causing an infection would still exist. Therefore, prior information regarding
these rare instances becomes highly relevant and the Bayesian analytical approach can ade-
quately address this issue. In brief, the Bayesian approach treats each time point as a set of
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prior information to build up towards the current information [6]. Therefore, integrating the
Bayesian approach within the WISCA framework can facilitate that rare pathogens are
accounted for [5]. The approach has previously been used to select appropriate empirical anti-
biotics for pediatric population with blood stream infections [5].
As part of tackling AMR, it’s also important to prevent misuse of antibiotics by improving
appropriate antibiotic selection. As such it is useful for policy makers and stewardship pro-
grams to provide recommendations of appropriate antibiotic choices for certain conditions.
An appropriate antibiotic choice should provide coverage to the causative pathogens. The
Bayesian WISCA approach can determine the antibiotics choices that are more likely to be
appropriate for empirical treatment. This can be achieved by selecting antibiotics with Bayes-
ian WISCA values closer to 1 (absolutely appropriate), while an antibiotic with a Bayesian
WISCA closer to or equal to 0 (absolutely inappropriate) harbors a high chance of failure.
As part of an international collaborative working group (Global Prevalence of Infections in
Urology–GPIU) for HAUTIs we have extensively reported on AMR [7–10], albeit accompa-
nied with the aforementioned limitations. HAUTIs are considered as complicated urinary
tract infections (UTI) and are associated with an increased morbidity and mortality rates [11].
The GPIU study is an annual surveillance study of HAUTIs in urology departments repeated
every year. A key feature of this study is the validated definitions used to capture episodes of
HAUTIs. In our previous analysis we illustrated high rates of AMR for both single antibiotics
and combination choices [7]. Although, these findings were useful we have been looking for a
better way to utilize the data and decided to explore the Bayesian WISCA approach, which will
allow identifying the appropriate antibiotics and thereby improve empirical treatment of
HAUTIs.
While appropriate use of antibiotics is crucial for efficacious treatment of patients with
HAUTIs, implementation of infection control policies (ICP) are of utmost importance to pre-
vent AMR and preserve effective antibiotics for the society. In departments with low compli-
ance to ICPs the AMR rates are expected to be higher compared to departments with better
compliance. Thus, the chances of coverage of empirical choices would be expected to decline
as the level of compliance with ICPs drop [12]. Unfortunately, measurement of the benefits of
ICPs is challenging and costly but here, the Bayesian WISCA approach could be an alternative
to compare different policies. We hypothesized that the self-reported ICP compliance would
impact on the Bayesian WISCA estimates and available choices of appropriate antibiotics.
In this study the primary aim was to determine the annual Bayesian WISCA of empirical
antibiotic choices for HAUTIs in European urology departments and to utilize the novel ana-
lytic approach to estimate the appropriate antibiotic choices. The secondary aim was to use
this probabilistic method to determine the impact of self-reported adherence to ICPs on the
available appropriate empirical antibiotic choices in HAUTIs. We used the GPIU study
sequential surveillance European data from 2005 to 2015 to estimate the Bayesian WISCA [1,
7–10, 13].
Material and methods
Data was obtained from an annual global surveillance study of HAUTIs conducted in urology
departments (GPIU study). For the current study data obtained from European centers only
(2005 to 2015) were used [7, 13]. The three objectives of this study were to;
i. Estimate the Bayesian WISCA of antibiotic choices and their time trend in HAUTIs;
ii. Estimate the appropriate antibiotic choices for HAUTIs; and
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iii. Estimate the impact of the reported ICPs adherence on chances of coverage of antibiotic
choices.
For the antibiotic choices the three outcomes that overlap with the objectives are reported
as;
i. Bayesian WISCA value;
ii. Number of appropriate antibiotic choices (1st quantile Bayesian WISCA value greater than
0.5); and
iii. Bayesian WISCA value in different ICP adherence groups and probabilistic differences.
Overview of definitions and methodological steps followed
The study included four steps to meet the defined objectives. These were as follows:
Step 1: Data collection and report of prevalence.
Step 2: Calculations of Bayesian WISCA.
Step 3: Evaluation of appropriateness of antibiotic choices.
Step 4: Comparison of investigator-reported ICP adherence groups.
Step-1: Data was collected from an annual surveillance study of HAUTIs in urology depart-
ments. HAUTI were defined according to the Center for Disease Control (CDC) criteria [14].
Analysis was limited to the European cohort only. The prevalence of HAUTIs, their causative
pathogens and susceptibility profiles towards antibiotics suitable for UTIs were obtained from
this data [7, 13].
Step-2: The probability of an antibiotic to cover the causative pathogens of the infectious
disease was calculated using the WISCA framework. Coverage means causative pathogens are
sensitive to the selected antibiotic. An illustration simplified of the principle is provided in Fig
1. WISCA was calculated by using the Bayesian approach, which allowed inclusion of prior
information (annual sequential data) and rare pathogens.
Step-3: Antibiotic choices were classified as either appropriate or inappropriate for empiri-
cal use in HAUTIs. This was determined using the Bayesian WISCA value. An antibiotic
choice was classified as appropriate if the chances of coverage exceeded its chances of not pro-
viding coverage. The approach is illustrated in Fig 2. The list of antibiotic agents recommended
for use in HAUTIs was obtained from international guidelines [15]. In total 18 antibiotics
choices (single:10 & combinations:8) were evaluated (S1 Table).
Step-4: The impact of ICPs on appropriate antibiotic choices was estimated by means of
simulation methods, which were reported in terms of probabilities. This approach allows
accounting for the uncertainty of each antibiotic choice’s coverage chances.
Step 1: Data collection—Annual surveillance of HAUTIs in urology
departments
The GPIU study is a point prevalence study of HAUTIs in urology departments, conducted
annually since 2003 [13]. The study protocol was amended in 2005 and data onwards was used
for consistency. The study is open for recruitment from urology departments on the same 13
days of November each year. Ethical approval for the study was left at the departments discre-
tion on the study years from 2003 to 2006 [16]. In 2007 a central ethical approval from Giessen
University ethical committee in Germany was obtained. Data provided by participating
Appropriate antibiotic choices in HAUTIs and impact of infection control policies
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departments was completely anonymized. The study is endorsed by the European Association
of Urology (EAU) and participating centers are provided a certificate of participation by the
EAU.
On the study day, all patients in the participating urology wards are screened for HAUTI
and surgical site infections (SSI). CDC criteria are used to determine an infection episode (S1
Appendix) [14]. Participating departments are required to provide information regarding
their hospital and urology department conditions and adherence to ICP. Clinical information
including culture specimens is collected from patients with an episode of HAUTI or SSI. Anti-
biograms are measured at the recruiting center laboratories. An antibiotic measured as
Fig 1. A hypothetical example of calculating WISCA. For purposes pf simplification, we assume that an infection can
only be caused by three pathogens (A, B and C). Their frequency in a surveillance study was 30%, 40% and 30% for
pathogen A, B and C respectively. For this disease there are two available antibiotics and Antibiotic 1 can only act
against pathogen A and antibiotic 2 can act towards pathogen B and C. In Fig 1A an “all sensitive” environment is
illustrated with the WISCA values for each antibiotic. In Fig 1B, an environment with “some resistance” is illustrated
with the accompanied impact on the WISCA values. WISCA is a compound measure of surveillance derived causative
pathogen frequency and susceptibility.
https://doi.org/10.1371/journal.pone.0214710.g001
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sensitive on an antibiogram (in vitro) is regarded as an appropriate choice for the episode of
infection [17].
From 2005 to 2015, 365 urology departments screened 22,263 cases and reported 1,468
(prevalence:6.6%) symptomatic HAUTIs with microbiological proof of infection. Summary of
patient acquisition according to STROBE guidance is provided in S1 Fig. Highest number of
registries was from European departments (n:1,181–80%), followed by Asia (n:165–12%),
Africa (n:42–3%) and Americas (n:36–2%). In 44 (3%) cases the geographical source of data
was missing. We used the data provided by the European centers for analysis due to insuffi-
cient annual sample size of other regions. Countries that provided data and the number of cen-
ters from each country are reported in S2 Table.
Step 2: Bayesian WISCA calculation
The WISCA approach was adopted within the Bayesian framework [5, 6]. This represents the
probability of an antibiotic to cover the causative pathogens for the surveyed infection. The
analytical approach is provided in detail within S1 Appendix [6]. Briefly two parameters are
used to calculate WISCA of an antibiotic: (i) probability of etiological pathogens; and (ii) prob-
ability of each etiological pathogen to be susceptible towards the studied antibiotic. WISCA is
calculated by: (a) first multiplying the probability of each etiological pathogen with the corre-
sponding probability of sensitivity of the studied antibiotic; and then (b) by adding those
Fig 2. Description of WISCA properties. WISCA is a probability for an antibiotic to be appropriate for a certain
infectious disease. Probabilities lie between 0 to 1. Therefore, if an antibiotic has a probability of 1 it is certain to cover
all possible causative pathogens whilst these pathogens are all sensitive towards the antibiotic. This information is
derived from surveillance of a population and therefore it cannot make inference to the possible effectiveness for an
individual, which requires consideration of pharmacokinetic variables.
https://doi.org/10.1371/journal.pone.0214710.g002
Fig 3. A practical example of calculating the WISCA for Amoxicillin in patients with symptomatic HAUTIs.
Values are given as means and 95% uncertainty range. Amoxicillin can act against wild type E.coli, Proteus spp,
Enterococcus spp, Coagulase (-) Staphylococcus (CONS) and other gram(+) isolates. The probability that each of these
isolates cause a symptomatic HAUTI within the GPIU data is; 0.42, 0.056, 0.1, 0.015 and 0.022 respectively. The
probability that each of these etiological pathogens are susceptible to Amoxicillin is; 0.37 (0.36–0.39), 0.39 (0.35–0.43),
0.69 (0.66–0.72), 0.20 (0.13–0.28) and 0.86 (0.80–0.90) respectively. The probability that Amoxicillin can cover each
respective pathogen is; 0.16 (0.42�0.37), 0.02 (0.057�0.39), 0.06 (0.1�0.69), 0.003 (0.015�0.20) and 0.086 (0.022�0.86). By
adding these probabilities up, the WISCA of Amoxicillin in HAUTIs is calculated to be 0.27.
https://doi.org/10.1371/journal.pone.0214710.g003
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obtained probabilities. To obtain the probability distribution of the WISCA we use the GPIU
prevalence data to simulate 1000 samples. A simplified example of WISCA calculation is pro-
vided in Fig 3.
Mainly we have two cores of calculations. The probabilities of etiological pathogens are
sampled through the Dirichlet distribution (p1,. . .,pn), where pj is the probability of pathogen
(j). The probability of an antibiotic choice to be sensitive to a certain pathogen is sampled
through the Beta distribution (sensitive, resistant). In both types we employ hierarchical
modelling techniques on the GPIU data from the preceding two years of each studied year to
calculate the informative priors. This is then combined with the raw data to obtain the poste-
rior distributions for each studied year and calculate the Bayesian WISCA. A sensitivity analy-
sis was conducted to determine the impact of the assumption of coding intermediate as
resistant in the data set.
Step 3: Appropriate empirical antibiotic choices for HAUTIs
Empirical treatment of patients with HAUTIs means that treatment is carried out in the
absence of culture results to guide treatment. Therefore, it is important to distinguish between
appropriate and inappropriate antibiotic choices. The empirical antibiotic choice will be
appropriate if two conditions are satisfied. These are;
i. The antibiotic should cover the causative pathogens; and
ii. The causative pathogen covered should be susceptible to the selected antibiotic choice.
The Bayesian WISCA identifies these two conditions and was used to classify antibiotic
choices (Fig 2) as appropriate or inappropriate. HAUTIs are complex infections and initial
empirical antibiotic treatment must be timely and effective. The consequences of failure of
treatment can be dire. Therefore, the risk of failure should be kept as low as possible whilst also
aiming to avoid antibiotic choices with high collateral damage.
In this study we sought to determine the number and characteristics (single agent vs multi-
ple agent) of antibiotic choices that are appropriate for empirical treatment with the lowest
possible risk of failure. In Fig 2 the principle of using the Bayesian WISCA value has been sum-
marized. A threshold of 0.5 for the Bayesian WISCA was used to determine the appropriate
antibiotic choices. In other words, a Bayesian WISCA above 0.5 represent greater chances of
the antibiotic choice to provide coverage.
While a Bayesian WISCA threshold of above 0.5 helps for classification, utilizing the
mean value alone cannot represent the uncertainty of the estimate in a useful way. The
Bayesian WISCA estimate uncertainty is the range of values it can achieve and is repre-
sented using the interquartile range (IQR). To account for the estimate uncertainty and
derive more robust decisions the IQR was used to establish thresholds. This is briefly illus-
trated in Fig 4.
Antibiotic choices with an estimated WISCA IQR below 0.5 are categorized as inappropri-
ate antibiotics. Their chances of appropriateness are less than inappropriateness within the
IQR of simulated samples. On the contrary antibiotic choices with an estimated WISCA IQR
above 0.5 represents chances of appropriateness greater than inappropriateness within the
IQR of simulated samples. Hence, those choices are categorized as appropriate antibiotics. For
antibiotic choices with an IQR that overlaps the probability of 0.5 we are uncertain with their
appropriateness. A summary of this stratification is provided in Table 1. A further threshold
analysis was conducted to calculate the estimated number of appropriate antibiotics if the
threshold was to be increased from 0.5 at an increment of 0.1 until no antibiotics remained
appropriate.
Appropriate antibiotic choices in HAUTIs and impact of infection control policies
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Step 4: Comparison of infection control policies
Adherence to two ICPs was reported by investigators. These are; catheter management policy
and policy for regulated usage of prophylactic antibiotics in urology departments. Based on
the reported ICP adherence, hospitals were stratified into three groups. These were;
• Complete adherence: adherence to both policies;
• Partial adherence: adherence to one policy amongst two; and
• Absence of ICP adherence: adherence to none of the two policies.
Fig 4. Example of how to estimate appropriateness of antibiotic choices. Antibiotic choices (single or multiple
agents) are classified as appropriate or inappropriate. This is achieved by utilizing the Bayesian WISCA value for each
choice. A threshold of 0.5 for the Bayesian WISCA value was selected. An antibiotic choice with a Bayesian WISCA
value greater than 0.5 means that the chance of coverage exceeds the chance of not providing coverage. The
interquartile range of the Bayesian WISCA was used to determine the appropriate antibiotics. This helped in
accounting for the uncertainty level of each antibiotic choice to classify as appropriate or not. In the examples given
antibiotic choice 1 has a mean Bayesian WISCA of 0.7 and 1st IQR value is 0.6. Since all simulated outcomes with this
choice remain above 0.5 it is classified as appropriate. The second antibiotic choice presented has an IQR extending
below 0.5 and despite a mean Bayesian WISCA of 0.5 is determined to be equivocal. The third antibiotic choice is
classified as inappropriate since all the IQR values is below 0.5.
https://doi.org/10.1371/journal.pone.0214710.g004
Table 1. Categorization of antibiotics according to the interquartile ranges of WISCA values.
WISCA IQR Appropriateness vs. inappropriateness Category
0–0.5 Appropriateness< inappropriateness
within the IQR of simulated samples
Inappropriate
0.5–1 Appropriateness> inappropriateness
within the IQR of simulated samples
Appropriate
IQR LB�<0.5 and
IQR UB
�
>0.5
Appropriateness< | >inappropriateness
within a group of the IQR of simulated samples
Equivocal
�LB: lower bound UB: Upper bound
https://doi.org/10.1371/journal.pone.0214710.t001
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Bayesian WISCA values were estimated for these three categories. Probabilistic comparison
was achieved with the inverse cumulative density function method to simulate 1000 WISCA
samples for each policy. This is followed by comparing each sample between groups to deter-
mine the probability of the WISCA to be greater than the comparator. This process classifies
each sample superior or not to the comparator for each antibiotic choice. A threshold of 75%
is used as an acceptable level for deducing conclusions on the trends. For example, if the Bayes-
ian WISCA values of an antibiotic in group x is greater than those of the same antibiotic in
group y in 75% of the sampled cases, then the antibiotic shows a trend of superior appropriate-
ness when applied in group x rather than in group y. Of note, conventional reporting of p-val-
ues was avoided within the Bayesian framework and estimates are presented with a degree of
certainty [18, 19].
Results
The analyzed data consisted of 1,468 cases from Europe diagnosed with HAUTI (according to
CDC criteria) from 2005 to 2015. The annual prevalence of HAUTIs in Europe ranged from
3.8% (2006) to 11.8% (2011). Urology departments from 29 countries across Europe provided
data. The number of patients screened, departments and countries participating, and preva-
lence of HAUTIs with culture proven infection annually are presented in Fig 5.
The mean age of patients was 63.8 (IQR: 55–76) and gender ratio was 2:1 for male to female.
The subgroups of diagnosis had a similar distribution (cystitis: 36.7%, pyelonephritis: 30.4%
and urosepsis:32.8%).
Antibiotic resistance rates
The sensitivity rates for E.coli ranged from 33% (Cefepime-2015) to 100% (Imipenem-except
2008) for single agents and from 75% (Ampicillin with Beta Lactamase Inhibitor (BLI) +-
Aminoglycosides in 2015) to 100% (all combinations in various years) for combinations.
These rates for E.coli were obtained from a sample size ranging from 3 cases (Cefepime–2015)
to 61 cases (Gentamicin-2014) (S3 Table). Sensitivity rates of pathogens against the antibiotic
choices are provided in S2 Fig.
Bayesian WISCA of antibiotics in HAUTIs
The annual estimated mean Bayesian WISCA of antibiotics in HAUTIs of single agents ranged
from 0.29 (IQR: 0.21–0.37) for Amp+BLI (2006) to 0.81(IQR:0.76–0.86) for Imipenem (2008)
(Fig 6). The estimated mean Bayesian WISCA of all combination options was above 0.5. The
lowest was estimated for Ciprofloxacin and Gentamicin combination in 2006 [mean:0.55
IQR:0.48–0.62] and 2009 [0.57 IQR:0.51–0.63]. Highest estimate was 0.87 [IQR:0.83–0.91] for
Imipenem and Amikacin combination in 2009.
Annual trends were not apparent for the estimated Bayesian WISCA. The highest mean
estimated Bayesian WISCA for single agents was for Imipenem in all consecutive years, which
was above 0.7 in all instances. In all years except for 2015 there was at least one combination
choice with an estimated Bayesian WISCA of greater than 0.8. Sensitivity analysis for the
Bayesian WISCA did not impact the values (S3 Appendix)
Appropriate empirical antibiotic choices for HAUTIs
The single agent antibiotic choices with a Bayesian WISCA IQR>0.5 were accepted as appro-
priate. Appropriate single agents were; Piperacillin+Tazobactam (2006–2014), Ceftazidime
(2007,2008,2013), Cefepime (2008, 2012–2014), Gentamicin (2008, 2011–2014), Amikacin
Appropriate antibiotic choices in HAUTIs and impact of infection control policies
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Fig 5. Annual number of patients screened, HAUTI prevalence, number of departments participating and
number of countries in the GPIU study carried out in Europe.
https://doi.org/10.1371/journal.pone.0214710.g005
Fig 6. Estimated Bayesian WISCA (informative prior) of antibiotic choices in HAUTIs reported in European urology departments from 2006 to 2015.
https://doi.org/10.1371/journal.pone.0214710.g006
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(2006–2008, 2010–2015), Imipenem (2006–2015) and Ciprofloxacin (2006, 2007, 2010, 2011).
Throughout all study years Amoxicllin+BLI, Cefuroxime and Cefotaxime were categorized as
inappropriate. Unlike the single antibiotic choices, all combination agents were classified as
appropriate throughout the study years except for 2009 where we were uncertain with one
combination choice.
The proportion of single agent antibiotics classified as appropriate (WISCA IQR>0.5) fluc-
tuated throughout the years without an obvious trend (Table 2). Highest rates (>60%) were in
2008, 2012 and 2013. For the remaining years the proportion of appropriate single agents were
50% and below. We estimated a consistent proportion of uncertain antibiotics in terms of
their appropriateness (10–30%).
Analysis of the established threshold was repeated with an increase of 0.1 increments. The
results for single agent antibiotic choices are illustrated in Fig 7. Apart from 2006 and 2011
none of the antibiotics were appropriate at a threshold of 0.8. A similar impact on the decline
in appropriate antibiotics was estimated for combination choices but at a threshold of 0.8 in a
few study years there was a single agent remaining appropriate (Fig 8). In the years 2008, 2011,
2012, 2013 and 2014 the number of appropriate antibiotics remained unchanged at a threshold
of 0.6 for the Bayesian WISCA.
Impact of ICPs on antibiotic choices
The Bayesian WISCA values of antibiotics in departments with different ICP adherences are
illustrated in Fig 9. The wide range of uncertainty in departments with absence of ICPs is of
notice owing to low sample size (S4 Table). Proportion of antibiotics that were appropriate
Table 2. Proportion of antibiotics categorized as appropriate, inappropriate and equivocal in HAUTIs.
Appropriateness 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Single antibiotic agents Inappropriate 40% 30% 20% 60% 50% 30% 20% 20% 30% 50%
Appropriate 30% 50% 70% 20% 30% 50% 60% 60% 50% 20%
Equivocal 30% 20% 10% 20% 20% 20% 20% 20% 20% 30%
Combination antibiotic agents Inappropriate 0 0 0 0 0 0 0 0 0 0
Appropriate 100% 100% 100% 87.5% 100% 100% 100% 100% 100% 100%
Equivocal 0 0 0 12.5% 0 0 0 0 0 0
https://doi.org/10.1371/journal.pone.0214710.t002
Fig 7. Appropriate antibiotics threshold analysis for single antibiotic choices. Incremental increases of 0.1 on the
threshold from 0.5 onwards to determine appropriate antibiotics for single agent choices. On y-axis the number of
appropriate antibiotics and on the x-axis the threshold value applied on the lower IQR is illustrated. Increase in
threshold has gradually declined the number of appropriate antibiotics.
https://doi.org/10.1371/journal.pone.0214710.g007
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ranged between 33%-88%, 27%-83% and 61%-91% for departments with absence, partial adher-
ence and complete adherence of ICPs respectively. An overall time trend is not apparent, and
we used the sampled method to compare superiority of WISCA between departments (Fig 10).
Partial adherence vs. absence of ICPs: The estimated WISCA IQRs showed overlap in most
time points in these two categories (Fig 9). We are uncertain if partial adherence provides an
improved estimated WISCA compared to absence of ICP. The number of superior antibiotic
choices in departments with partial ICP adherence compared to complete absence of ICP
adherence ranged between 0 (2007–2008) to seven (39%) over the study years (Fig 10).
Complete adherence vs partial adherence: The number of superior antibiotic choices over
the study years ranged between two (11%) (2007–2008) to 16 (88%) (2013) (Fig 10). Amongst
eight combination agent choices except for Amp/BLI+Gentamicin and Ciprofloxacin+-
Amikacin all remaining options estimated Bayesian WISCA was superior in departments with
complete adherence to ICPs (Fig 10).
Complete adherence vs. absence of ICP: Number of superior estimates of antibiotic choices
ranged between 0 (2007–2008) to 13 (72%) (2015) (Fig 10). From 2008 onwards, the complete
adherence group exhibited at least 4 (22%) (2014) antibiotic choices that were superior.
Discussion
We evaluated the chances of coverage of empirical antibiotic choices through the Bayesian
WISCA in European urology departments for HAUTIs defined by strict criteria (CDC) over a
period of 10-years. We estimated that the mean Bayesian WISCA value for single agent antibi-
otic choices ranged from 0.29 (Amp+BLI in 2006) to 0.81 (Imipenem 2008). Combination of
antibiotic choices showed an increase in the estimates. By further utilizing the analytic meth-
ods we were able to stratify the antibiotic choices as appropriate, inappropriate and equivocal
for empirical treatment of HAUTIs. We estimated that half of the single antibiotic agents are
inappropriate and for one third of them we are uncertain. In our estimates all combination
agents remained appropriate throughout the study years. Our analytical approach has also
demonstrated that self-reported adherence to a range of infection prevention policies coincides
with higher number of antibiotic choices.
Chance of providing coverage (WISCA) is a relatively new concept for evaluating antibiot-
ics by accounting for both frequency of HAUTI pathogens and their respective AMR [17, 20,
21]. To our knowledge there are no studies in the published literature that utilized this
Fig 8. Appropriate antibiotics threshold analysis for combination antibiotic choices. Incremental increases of 0.1
on the threshold to determine appropriate antibiotics for combination agent choices. On y-axis the number of
appropriate antibiotics and on the x-axis the threshold value applied on the lower IQR is illustrated. Increase in
threshold has gradually declined the number of appropriate antibiotics.
https://doi.org/10.1371/journal.pone.0214710.g008
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approach for HAUTIs. A study from Netherlands in 2012 used the method for complicated
UTIs but lacked validated instruments to capture clinical information and characterize infec-
tions [22]. On the contrary, we studied a very specific population by using stringent criteria
(CDC definitions) for the diagnosis of HAUTI. Therefore, we were able to distinguish asymp-
tomatic bacteriuria and exclude these patients that constitute approximately one third of the
population detected through screening of inpatients [16]. Ensuring a specific population is a
key strength of our study but beyond that utilizing the WISCA in a surveillance study is limited
as rare pathogens cannot be accounted for. To overcome this the Bayesian analytical approach
was utilized, which to our knowledge was first used by Bielicki J.A. et al [5]. In their study, the
Bayesian WISCA was used to select appropriate empirical antibiotics for blood stream infec-
tions in a pediatric population. However, they used a non-informative prior, which means
they didn’t account for prior year surveillance data. In our study we used robust validated
methods (hierarchical modelling) to include the prior year data (informative prior) when cal-
culating the Bayesian WISCA value [6]. In brief, inclusion of the Bayesian approach into
WISCA with an informative prior has facilitated to obtain probabilities of coverage for antibi-
otic choices with their respective level of uncertainty.
The Bayesian WISCA values of the studied antibiotics showed fluctuations over the 10-year
period but lacked a clear time trend. We further assessed the antibiotic choices by establishing
cut-off values to determine if an antibiotic would be an appropriate choice for empirical
Fig 9. Estimates of Bayesian WISCA (with informative prior) of antibiotic choices per infection prevention policy in HAUTIs from urology departments
reported in Europe from 2006 to 2015.
https://doi.org/10.1371/journal.pone.0214710.g009
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treatment. Similarly, this approach also did not demonstrate a time trend in the proportion of
appropriate antibiotic choices. However, this finding should be interpreted with caution as we
are uncertain with at least 20% of single agent choices. We also conducted a threshold analysis,
whereby the threshold was gradually increased at an increment of 0.1. This demonstrated that
in several years the threshold could be increased to 0.6 without a decrease in the number of
appropriate antibiotics. This exploratory analysis is particularly important as it can be utilized
in local surveillance data to establish the optimal decision for appropriate antibiotic lists whilst
controlling for risk of failure.
It should be emphasized that by classifying an antibiotic as inappropriate in this study we
are not suggesting them to be redundant and we encourage their utility in the presence of cul-
ture and sensitivity results if proven to be sensitive. Optimal antibiotic selection approaches
are still to be discovered, but in our study, we confirmed that combination options improve
the Bayesian WISCA proposing a plausible strategy for complicated, severe HAUTIs such as
urosepsis. For example, the mean Bayesian WISCA estimate of Amp+BLI alone ranged
between 0.29 (IQR:0.26–0.34, 2006) to 0.46 (IQR:0.43–0.49, 2014) and for Gentamicin alone
ranged from 0.46 (IQR:0.43–0.50, 2006) to 0.65 (IQR:0.62–0.67, 2013). The combination of
these two antibiotics lead to a substantial increase in the mean Bayesian WISCA estimate rang-
ing from 0.56 (2006, IQR:0.53–0.61) to 0.76 (2012, IQR:0.72–0.79). This combination choice,
Fig 10. Probability that Bayesian WISCA of the antibiotic choice at the particular year is superior in the departments "x" compared with department "y"
(departments are stratified according to the number infection control policy adherence).
https://doi.org/10.1371/journal.pone.0214710.g010
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like other Beta-lactam and Aminoglycoside combinations, is estimated to have a similar
chance of coverage with broad spectrum antibiotics such as Imipenem and Piperacillin/Tazo-
bactam that should be conserved as much as possible in the face of increasing antibiotic resis-
tance. The examples provided illustrate the need for careful interpretation of the obtained
estimates. Moreover, the Bayesian WISCA can facilitate finding effective strategies for select-
ing appropriate antibiotics for empirical treatment. We would also stress out the importance
of making better choices of empirical treatments with the Bayesian WISCA. If one opts to
obtain an absolute certainty of complete coverage of pathogens with empirical treatment the
Bayesian WISCA (estimate of 1 with no uncertainty) then multiple agents and classes of antibi-
otics would be combined. This would, however, defeat the purpose of antibiotic stewardship
and optimization of choices.
As part of our work we carried out an exploratory analysis of the impact of ICPs on appro-
priate antibiotics through the Bayesian WISCA tools. ICPs can reduce the need (less infection
episodes) and demand (responsible use) for antibiotics [23]. The policies evaluated in our
study were adherence to urinary catheter care and regulation of antibiotic usage for prophy-
laxis. The first policy is expected to decrease catheter associated UTIs hence reducing the need
for antibiotics. The second is associated with a decline in the demand for antibiotics. We have
estimated that compliance to both ICPs is necessary to achieve the benefits in terms of higher
level of appropriate antibiotics (Fig 10). These findings highlight the importance of adhering
to ICPs and the need for an extensive policy approach. Nevertheless, the estimates for the ICPs
should be considered with caution since we lack detailed knowledge about the implementation
and the strategies employed [24]. In our study investigators provided information on self-per-
ceived adherence to the policies, which underline the need for a more detailed survey of this
information. We therefore suggest that future studies should utilize the Bayesian WISCA
framework to obtain comparable and reliable outcomes, which is one of the main difficulties
of infection related policy studies. In our study, comparison of ICPs was carried out by utiliz-
ing probabilistic and simulation methods.
Despite the advantages of the novel approach we adopted in analyzing HAUTIs there are
certain limitations that require attention. Firstly, the GPIU surveillance study gathers data
from urology departments through an altruistic contribution. Therefore, insufficient sampling
of the HAUTI population is of concern. However, departments contributing to this study do
have a high level of awareness of AMR issues. Therefore, even if our results are based on an
incomplete representation, its more likely to be the optimal section of the population. Sec-
ondly, only two ICPs were evaluated and unfortunately the local practice of these ICPs is not
known. Thirdly, these estimates represent a sampled population in Europe at given time points
and cannot be used to derive local empiric antibiotic policies. By pooling different hospital
data, the inter-hospital heterogeneity has not been accounted for. We could have preferred to
subgroup the samples of each hospital, but this would lead to very low sample sizes and unreli-
able estimates. Studies to assess inter-hospital heterogeneity as part of the Bayesian WISCA are
required. Nevertheless, our study does provide an overall trend over a 10-year period in urol-
ogy practice. Finally, we have not accounted for the geographical variation in Europe. This was
due to insufficient data to represent certain areas and would generate uncertain results
although the mean estimates would not change.
In conclusion, we were able to estimate that there was no clear time trend in chances of cov-
erage of the antibiotic choices in European urology departments. Departments with self-
reported adherence to ICPs have more antibiotic choices. Future studies should focus on
determining the optimal selection of antibiotics for subgroups of HAUTIs. Moreover, the
Bayesian WISCA approach adopted should be repeated in local surveillance studies to improve
local policy recommendations.
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